
OGN AI Price Prediction
Track OGN's AI-powered predictions, market trends, and investment insights.
You don't hold OGN in your mock portfolio yet.
Track OGN's AI-powered predictions, market trends, and investment insights.
You don't hold OGN in your mock portfolio yet.
Upgrade to see the full Evidence Stack
What Changed, Why Now, and Risk Flags — available on the Investor plan and above
Get StartedWith EPS at 0.93 and a PE ratio of 14.39, Organon & Co. appears reasonably valued versus many pharma peers, suggesting the market is pricing in modest, not high, growth. Profitability exists but is not strong enough, based on the given data, to imply a clear high-growth or high-margin story. Absent more detailed revenue and margin trends, the picture is one of stable but unspectacular financial performance.
The stock at $13.38 is trading well above its 200-day moving average of $8.77, indicating a strong intermediate-term uptrend. A 1.0% gain over the last month is modest, but the large gap above the 200-day average suggests prior strong momentum and improving sentiment. Without an extreme valuation or evidence of overbought conditions provided, the technical setup leans moderately bullish.
Alternative data show constructive signs, particularly the sharp increase in job openings and steady growth in professional-network followers. Web traffic is at a meaningful level, and LinkedIn growth plus a 180.5% month-over-month jump in job postings point to expansion and investment in the business. Social media metrics are mixed at the margin but overall skew slightly positive.
Organon & Co. shows a technically strong stock price relative to its 200-day moving average and constructive alternative data, especially in hiring and professional engagement. However, based on the limited financial detail provided, earnings and valuation appear more steady than aggressively growth-oriented, tempering the overall view. Taken together, the setup leans neutral with a slight positive tilt, contingent on continued earnings stability or improvement.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.


Orogen Reports Strong Q1 2026 Results with 144% Growth in Net Income

Organon to Present New Research on Access and Value at ISPOR 2026

Orogen Royalties Appoints Mr. Chad Wells to the Board of Directors
Organon & Co. (OGN) is currently trading at $13.36 on the NYSE, carrying a market capitalization of approximately $3.5 billion. Daily volume of over 2.1 million shares reflects moderate investor activity, while the stock posted a modest single-day decline of 0.3%. Organon's portfolio spans women's health — anchored by the contraceptive implant Nexplanon — alongside a growing biosimilars segment featuring immunology and oncology products, and an established cardiovascular franchise. The company operates across both U.S. and international markets, providing geographic diversification relative to many specialty pharma peers.
TrendEdge's AI model assigns OGN a score of 6 out of 10, placing it in neutral-to-cautiously-positive territory. This mid-range score reflects a balance between Organon's diversified revenue base and its ongoing challenges, including debt carried over from its 2021 spinoff from Merck. The 251 active job postings signal continued operational investment, particularly relevant to product development and commercialization efforts. Social sentiment data is sparse, with only 2 Reddit mentions in the past week, suggesting limited retail investor enthusiasm — a factor the AI model weighs as a neutral-to-slightly-negative momentum signal.
Key catalysts for OGN in 2026 include biosimilar market share gains, particularly for Hadlima and Renflexis in the competitive immunology space, and continued Nexplanon adoption in international markets. The primary risks remain elevated leverage, patent exposure across the established brands portfolio, and pricing pressure on biosimilars. Investors should monitor quarterly earnings for debt reduction progress and any pipeline updates in women's health, as these will likely be the strongest determinants of whether OGN can sustain or build on its current valuation.
Unlock comprehensive alternative data signals to make better investment decisions
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
Web Traffic
173,519
Twitter Followers
738
Instagram Followers
9,888
YouTube Subscribers
542
LinkedIn Followers
190,296
Job Postings
236
LinkedIn Employees
6,979
News Mentions
0
Key Metrics